Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240953 | 0.87 | ALDH1A1 (0.33) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL13996173 | 0.83 | ALDH1A1 (0.36) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL241749 | 0.82 | KMT2A (0.42) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL13993588 | 0.82 | ALDH1A1 (0.33) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL4983642 | 0.81 | GABRA1 (0.40) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL251636 | 0.77 | TDP1 (0.38) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL238448 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HTTKDM4ELMNANPSR1 | |
| SCHEMBL13996246 | 0.76 | ALDH1A1 (0.34) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL13996154 | 0.73 | ALDH1A1 (0.38) | KMT2AALDH1A1MEN1HTTKDM4E | |
| SCHEMBL242600 | 0.73 | ALDH1A1 (0.36) | KMT2AALDH1A1MEN1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012015875-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015901-A1 | METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2286812-A1 | Solubilized topoisomerase poisons | Rutgers, The State University (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7781587-B2 | antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2010088544-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2196205-A1 | Topoisomerase poisons | Rutgers, The State University (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1465625-B1 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-09-24 | — | — | US | disclosed |
| US-7517883-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7049315-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060052381-A1 | Solubilized topoisomerase poisons | LAVOIE EDMOND J | 2006-03-09 | — | — | US | disclosed |
| EP-1465625-A4 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050009824-A1 | Solubilized topoisomerase poisons | RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE | 2005-01-13 | — | — | US | disclosed |
| EP-1465625-A2 | SOLUBILIZED TOPOISOMERASE POISONS | Rutgers, The State University (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009824-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | KMT2A 1606/4885ALDH1A1 3459/4885MEN1 2154/4885 |
| US-20090239871-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | KMT2A 1606/4885ALDH1A1 3459/4885MEN1 2154/4885 |
| US-20120004235-A1 | METHODS TO TREAT CANCER | TP53, CCNY, ABCB1 | KMT2A 656/4885ALDH1A1 115/4885MEN1 288/4885 |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | KMT2A 1606/4885ALDH1A1 3459/4885MEN1 2154/4885 |
| US-20060052381-A1 | Solubilized topoisomerase poisons | TOP1, TOP2A, TOP2B | KMT2A 1606/4885ALDH1A1 3459/4885MEN1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.